J&J and Debiopharm get stakes in Biocartis, as part of 30 million-euro financing round

9 April 2010

Biocartis SA, a Swiss biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics, announced the successful closing of a Series B equity financing round. The Company raised 30 million ($41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.

The new investors are the fellow Switzerland-based Debiopharm and US drug major Johnson & Johnson's Development Corporation unit, each thus obtaining a minority stake in Biocartis.

This financing round was also underwritten by Aescap, Biocartis' original lead-investor (The Netherlands), Biovest (Belgium), Advent Venture Partners (UK), several Biocartis employees and Benaruca, the family investment vehicle of Biocartis' co-founder Rudi Pauwels.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK